Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment
Conventional cancer therapies have many limitations. In the last decade, it has been suggested that bacteria-mediated immunotherapy may circumvent the restrictions of traditional treatments. For example, Salmonella enterica is the most promising bacteria for treating cancer due to its intrinsic abil...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1293351/full |
| _version_ | 1797404543416270848 |
|---|---|
| author | Genesy Pérez Jorge Marco Túlio Pardini Gontijo Marcelo Brocchi |
| author_facet | Genesy Pérez Jorge Marco Túlio Pardini Gontijo Marcelo Brocchi |
| author_sort | Genesy Pérez Jorge |
| collection | DOAJ |
| description | Conventional cancer therapies have many limitations. In the last decade, it has been suggested that bacteria-mediated immunotherapy may circumvent the restrictions of traditional treatments. For example, Salmonella enterica is the most promising bacteria for treating cancer due to its intrinsic abilities, such as killing tumor cells, targeting, penetrating, and proliferating into the tumor. S. enterica has been genetically modified to ensure safety and increase its intrinsic antitumor efficacy. This bacterium has been used as a vector for delivering anticancer agents and as a combination therapy with chemotherapy, radiotherapy, or photothermic. Recent studies have reported the antitumor efficacy of outer membrane vesicles (OMVs) derived from S. enterica. OMVs are considered safer than attenuated bacteria and can stimulate the immune system as they comprise most of the immunogens found on the surface of their parent bacteria. Furthermore, OMVs can also be used as nanocarriers for antitumor agents. This review describes the advances in S. enterica as immunotherapy against cancer and the mechanisms by which Salmonella fights cancer. We also highlight the use of OMVs as immunotherapy and nanocarriers of anticancer agents. OMVs derived from S. enterica are innovative and promising strategies requiring further investigation. |
| first_indexed | 2024-03-09T02:56:31Z |
| format | Article |
| id | doaj.art-e11457cfb6cb48aabe1f992b02b75f1d |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-03-09T02:56:31Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-e11457cfb6cb48aabe1f992b02b75f1d2023-12-05T04:39:00ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882023-12-011310.3389/fcimb.2023.12933511293351Salmonella enterica and outer membrane vesicles are current and future options for cancer treatmentGenesy Pérez Jorge0Marco Túlio Pardini Gontijo1Marcelo Brocchi2Universidade Estadual de Campinas (UNICAMP), Departamento de Genética, Evolução, Microbiologia e Imunologia, Laboratório de Doenças Tropicais, Instituto de Biologia, Campinas, BrazilDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, United StatesUniversidade Estadual de Campinas (UNICAMP), Departamento de Genética, Evolução, Microbiologia e Imunologia, Laboratório de Doenças Tropicais, Instituto de Biologia, Campinas, BrazilConventional cancer therapies have many limitations. In the last decade, it has been suggested that bacteria-mediated immunotherapy may circumvent the restrictions of traditional treatments. For example, Salmonella enterica is the most promising bacteria for treating cancer due to its intrinsic abilities, such as killing tumor cells, targeting, penetrating, and proliferating into the tumor. S. enterica has been genetically modified to ensure safety and increase its intrinsic antitumor efficacy. This bacterium has been used as a vector for delivering anticancer agents and as a combination therapy with chemotherapy, radiotherapy, or photothermic. Recent studies have reported the antitumor efficacy of outer membrane vesicles (OMVs) derived from S. enterica. OMVs are considered safer than attenuated bacteria and can stimulate the immune system as they comprise most of the immunogens found on the surface of their parent bacteria. Furthermore, OMVs can also be used as nanocarriers for antitumor agents. This review describes the advances in S. enterica as immunotherapy against cancer and the mechanisms by which Salmonella fights cancer. We also highlight the use of OMVs as immunotherapy and nanocarriers of anticancer agents. OMVs derived from S. enterica are innovative and promising strategies requiring further investigation.https://www.frontiersin.org/articles/10.3389/fcimb.2023.1293351/fulldelivery vectorcombination therapynanocarriersouter membrane vesiclesSalmonella Typhimuriumimmunotherapy |
| spellingShingle | Genesy Pérez Jorge Marco Túlio Pardini Gontijo Marcelo Brocchi Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment Frontiers in Cellular and Infection Microbiology delivery vector combination therapy nanocarriers outer membrane vesicles Salmonella Typhimurium immunotherapy |
| title | Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment |
| title_full | Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment |
| title_fullStr | Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment |
| title_full_unstemmed | Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment |
| title_short | Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment |
| title_sort | salmonella enterica and outer membrane vesicles are current and future options for cancer treatment |
| topic | delivery vector combination therapy nanocarriers outer membrane vesicles Salmonella Typhimurium immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1293351/full |
| work_keys_str_mv | AT genesyperezjorge salmonellaentericaandoutermembranevesiclesarecurrentandfutureoptionsforcancertreatment AT marcotuliopardinigontijo salmonellaentericaandoutermembranevesiclesarecurrentandfutureoptionsforcancertreatment AT marcelobrocchi salmonellaentericaandoutermembranevesiclesarecurrentandfutureoptionsforcancertreatment |